Given that BRAF inhibitors and MEK inhibitors are increasingly used in the adjuvant setting, adequate monitoring and treatment of hypertension is of even greater importance to reduce the risk of developing cardiovascular disease in the longer term. This evidence concerns the gene MAP2K7 and hypertensive disorder.